Brain Ischemia – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Brain Ischemia – Pipeline Review, H2 2016’, provides an overview of the Brain Ischemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Brain Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Ischemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Brain Ischemia

The report reviews pipeline therapeutics for Brain Ischemia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Brain Ischemia therapeutics and enlists all their major and minor projects

The report assesses Brain Ischemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Brain Ischemia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Brain Ischemia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Brain Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CohBar, Inc.

Lixte Biotechnology Holdings, Inc.

NeuroNascent, Inc.

NeurOp, Inc

Prolong Pharmaceuticals, LLC

Spectrum Pharmaceuticals, Inc.

Sylentis S.A.U.

Vect-Horus S.A.S.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Brain Ischemia Overview 7

Therapeutics Development 8

Pipeline Products for Brain Ischemia - Overview 8

Pipeline Products for Brain Ischemia - Comparative Analysis 9

Brain Ischemia - Therapeutics under Development by Companies 10

Brain Ischemia - Therapeutics under Investigation by Universities/Institutes 11

Brain Ischemia - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Brain Ischemia - Products under Development by Companies 14

Brain Ischemia - Products under Investigation by Universities/Institutes 15

Brain Ischemia - Companies Involved in Therapeutics Development 16

CohBar, Inc. 16

Lixte Biotechnology Holdings, Inc. 17

NeuroNascent, Inc. 18

NeurOp, Inc 19

Prolong Pharmaceuticals, LLC 20

Spectrum Pharmaceuticals, Inc. 21

Sylentis S.A.U. 22

Vect-Horus S.A.S. 23

Brain Ischemia - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

2-CCPA - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AB-002 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

ADA-409 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Humanin - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

LAU-0901 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

LB-100 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

NP-10679 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

phycocyanobilin - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Sanguinate - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules for Brain Ischemia - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Antagonize Gpr17 for Brain Ischemia - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SPI-1620 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Stem Cell Therapy for Ischemia - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Synthetic Peptide for Central Nervous System Disorders - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

VHN-439 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Brain Ischemia - Dormant Projects 54

Brain Ischemia - Discontinued Products 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

Number of Products under Development for Brain Ischemia, H2 2016 8

Number of Products under Development for Brain Ischemia – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Brain Ischemia – Pipeline by CohBar, Inc., H2 2016 16

Brain Ischemia – Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 17

Brain Ischemia – Pipeline by NeuroNascent, Inc., H2 2016 18

Brain Ischemia – Pipeline by NeurOp, Inc, H2 2016 19

Brain Ischemia – Pipeline by Prolong Pharmaceuticals, LLC, H2 2016 20

Brain Ischemia – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 21

Brain Ischemia – Pipeline by Sylentis S.A.U., H2 2016 22

Brain Ischemia – Pipeline by Vect-Horus S.A.S., H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Brain Ischemia – Dormant Projects, H2 2016 54

Brain Ischemia – Dormant Projects (Contd..1), H2 2016 55

Brain Ischemia – Discontinued Products, H2 2016 56

List of Figures

List of Figures

Number of Products under Development for Brain Ischemia, H2 2016 8

Number of Products under Development for Brain Ischemia – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports